ArticleBritish journal of clinical pharmacology2003

Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.

Karin Hellman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.